Latest in Newer

Sort by

2 items

AbbVie’s newer immunology drugs are offsetting Humira’s decline, sending stock up 5%

AbbVie’s earnings topped estimates, and it offered an upbeat view of 2025.
MarketWatch - 5h
We're buying more of a newer stock that is wisely pushing into a fast-growing market

We first added the company to our portfolio in October.
CNBC - Jan. 8